Dr. Adam Muzychuk

Call Directions Website

Dr. Adam Muzychuk Calgary Ophthalmologist (MD) with interests in:
• Refractive & Laser Vision Correction
• Cataract Surgery & Anterior Segment

From the September issue of Cataract & Refractive Surgery Today, an editorial insert on advances in full-range-of-vision...
10/09/2026

From the September issue of Cataract & Refractive Surgery Today, an editorial insert on advances in full-range-of-vision intraocular lenses, particularly enVista Envy, exploring how the technology works, what clinical research tells us about patient outcomes, and how these advances should influence patient selection and surgical planning.

Most importantly, are we ensuring that patients are being counselled and offered modern implants based on technology as it exists today, or are our experiences with these types of implants as they existed in 2016 still influencing how we perform surgery in 2026?

Spent part of a beautiful Louisiana morning recording an episode of CRST: The Podcast (Cataract and Refractive Surgery T...
10/09/2026

Spent part of a beautiful Louisiana morning recording an episode of CRST: The Podcast (Cataract and Refractive Surgery Today) with Dr. Steven Dell of Dell Laser Consultants in Austin, Texas.

We discussed contemporary full-range-of-vision intraocular lenses, including innovations in engineering, how these advances are shaping patient counselling and visual outcomes, approaches to astigmatism management, and the nuances that distinguish today’s technologies.

Thanks to CRST for having us, looking forward to sharing the episode when it’s released.

An incredible few days in London during .Highlights from the meeting included taking part in two ESCRS Arena sessions, ...
10/07/2026

An incredible few days in London during .

Highlights from the meeting included taking part in two ESCRS Arena sessions, one on AI vs surgeon planning and another on cataract complications, along with presenting research on enVista Envy and TECNIS PureSee, as well as leading a Meet the Expert session in the exhibition hall. Every time I see my name on the display for Meet the Expert, I wonder about an administrative error.

Outside the meeting, I had the opportunity to share years of research and surgical experience with enVista Envy at several events across London as part of its UK and Ireland launch.

On a personal note, there was also time to explore some new and familiar parts of London, catch up with new and old friends, including a personal reading by J. Morgan Micheletti, MD, FACS from his newest textbook, along with an overnight in Oxford to catch up with old friends outside of medicine and surgery.

And finally, an announcement: it’s my great pleasure to share that David Lockington, President-Elect of UKISCRS and one of the most in-demand surgeons in ophthalmology globally, will be joining us at the EPSAA Scientific Meeting in Banff, Alberta, at the end of January. Dr Ben LaHood we’re coming for you in the near future.

Congratulations to Dr. Lockington and the ESCRS Planning Committee on an outstanding program in London.

Until next year, ESCRS.

Could not be more excited to be at the 44th Congress of ESCRS, and in particular to have been invited to participate in ...
09/10/2026

Could not be more excited to be at the 44th Congress of ESCRS, and in particular to have been invited to participate in my first ESCRS Arena debate, discussing AI and adjustability in surgical planning.

Congratulations to the organizers on an incredible program, including the great David Lockington, President-Elect of UKISCRS, and thank you to ESCRS for the invitation.

Outside the main meeting, I’ll also be at several events supporting the UK launch of enVista Envy. Looking forward to a fantastic few days in London.

Growing up in Canada, I never imagined the first time I’d professionally put on hockey gear would be for a telecast on s...
08/07/2026

Growing up in Canada, I never imagined the first time I’d professionally put on hockey gear would be for a telecast on surgery.

Had an incredible time discussing my experience with TECNIS PureSee and TECNIS Odyssey as a guest of Erin, Gary Wörtz, MD and Blake Williamson on the JJSV US/Canada telecast. Thank you to Johnson & Johnson Surgical Vision for the invite, and congrats to the professional education team.

First author is primary, last author is senior, but twelfth author? Vibes guy.On top of the usual, I’m on the aux cable ...
07/25/2026

First author is primary, last author is senior, but twelfth author? Vibes guy.

On top of the usual, I’m on the aux cable during research calls and hyping up the team on email chains. Academic version of being the dressing room guy in team sports.

This paper is critically important.

As a field, we lack a standardized way to describe, measure, and report dysphotopsias after cataract surgery, refractive surgery, and laser peripheral iridotomy, one of the key optical limitations of the procedures and technologies we offer.

Almost every paper uses a different classification system, a different questionnaire and rating scale, and a different way of reporting. The problem isn’t just that we need better trials. Trials evaluating IOLs, LPI, and other anterior segment interventions have been run, but differences in how dysphotopsias are measured and reported make it difficult to even indirectly compare their results across studies.

This work gives us a common language: a standardized classification system and questionnaire, the DYsphotopsia Symptom Questionnaire and Outcomes, or DYSQO, developed through systematic review and Delphi consensus among 20 specialists in cataract/refractive, glaucoma, and cornea surgery from six countries, nominated by ophthalmology societies. It’s an important building block for making future research more comparable, more useful, and more immediately meaningful for patients and surgeons.

It’s open access, and the questionnaire is free to use without permission.

Congratulations to Ryan Huang and the team at UofT for taking on this incredibly complex topic and getting this building block across the finish line.

Post Malone is on deck.

Standardized Classification System for Dysphotopsia Reporting
Ophthalmology Glaucoma, 2026

https://doi.org/10.1016/j.ogla.2026.06.005

Standing room only at ‘Vision Redefined: A Panel Discussion on Premium Cataract Solutions’, a discussion with Mahshad Da...
06/19/2026

Standing room only at ‘Vision Redefined: A Panel Discussion on Premium Cataract Solutions’, a discussion with Mahshad Darvish MD, Darren Albert MD, and welcoming back Patricia Piers PhD (Netherlands) and Ashley Brissette (NYC). Discussing surgery and engineering with global experts was a dream. Thank you to Johnson & Johnson Surgical Vision for the invitation.

Two years ago today, I performed the world’s first enVista Envy implant, after leading the Canadian clinical trial. Here...
06/05/2026

Two years ago today, I performed the world’s first enVista Envy implant, after leading the Canadian clinical trial. Here’s what we’ve learned since.

Two years, two peer-reviewed publications, research data presented across North America, Europe and Asia, and last night discussing with colleagues in Kelowna.

DYSPHOTOPSIAS: WE’RE FRAMING THEM INCORRECTLY
In the Canadian trial, halos and starbursts were more frequent or severe than with a monofocal lens. But bothersomeness was no different from monofocals. Patients notice these phenomena but aren’t more bothered by them. That gap is the whole conversation and should change how we counsel. Real-world data (Cancun 2026): only 2.1% spontaneously reported any dysphotopsia. Logistic regression (Copenhagen 2025) showed no significant relationship between residual cylinder and dysphotopsias. None of us are perfect, and with this IOL, we don’t have to be.

THE DEFOCUS CURVE: INTELLIGENT DESIGN
Pupil-stratified data (AAO 2024) is where the ActivSync optic shows its hand. Under mesopic conditions the design becomes increasingly distance-dominant. With large pupils (>4.0mm), distance and near stay relatively preserved while intermediate gives up ground. This is a feature, not a bug. Intermediate tasks in dim light are disproportionately backlit, think tablets, laptops, and computer screens. Preserving distance and near while allowing some loss at intermediate is a surprisingly rational place to spend a photon budget. Patients agree: 84.3% reported no or only a little difficulty seeing close objects in dim lighting. The reflexive concern, or worse, the competitive marketing, that apodized optics abandon patients in low light doesn’t survive contact with the data.

TREAT THE SMALLEST AMOUNTS OF ASTIGMATISM
Our ultra-low cylinder toric study (Muzychuk & Kranemann 2026) showed treating the smallest amounts produced significantly better refractive outcomes than leaving them alone, using basic equipment, careful measurements, and an optimized ocular surface. The old rule of leaving small astigmatism alone is not supported.

I know eye surgeons who got these implanted themselves, which says it all.

Thank you to B+L. What a ride.

Honoured to spend last Wednesday at the University of Ottawa to deliver Visiting Professor Grand Rounds, then resident a...
05/19/2026

Honoured to spend last Wednesday at the University of Ottawa to deliver Visiting Professor Grand Rounds, then resident and fellow teaching rounds.

Grand Rounds covered a wide range of topics spanning modern cataract and refractive surgery, including biometry and formulas, IOL calculations, evidence-based management of astigmatism, contemporary full-visual range IOLs, and advanced phaco techniques on a venturi platform. With ~120 slides in 50 minutes, I have zero academic chill.

In teaching rounds we reviewed IOL material science, spherical and chromatic aberration, MTF and defocus curves, challenging cases in surgical planning, as well as management of refractive surprises and adverse effects of contemporary full-visual range IOLs.

One of the highlights was spending time at the Ottawa Eye Institute with Mona Koaik, MD, and Setareh Ziai, MD, two star surgeons I’ve collaborated with at meetings in the past.

Always energizing to connect with colleagues who are passionate about pushing cataract and refractive surgery forward while investing deeply in education and mentorship. Thanks again to the entire University of Ottawa ophthalmology program for the warm welcome and hospitality.

Featured throughout this month’s Review of Ophthalmology cover story on the newest premium IOLs: TECNIS PureSee, enVista...
05/14/2026

Featured throughout this month’s Review of Ophthalmology cover story on the newest premium IOLs: TECNIS PureSee, enVista Envy, TECNIS Odyssey, Clareon PanOptix Pro, and FineVision HP, alongside my US colleagues George O. Waring IV, MD; John Hovanesian, MD; Richard Davidson, MD; Karl Stonecipher, MD; and Joseph Christenbury, MD.

In this interview, I weigh in on:

TECNIS PureSee. A purely refractive, pupil-independent EDOF that has shown no significant decrease in contrast sensitivity compared to monofocal controls in studies to date, including the recent FDA IDE. Given the uncompromised quality of vision, coupled with impressive tolerance to residual refractive error, I share excellent experience in post-refractive eyes (which we’ll present at ESCRS 2026) where exact targets are harder to hit.

enVista Envy. A continuous full-visual-range (FVR) IOL with no significant difference in bothersomeness to glare, halos, or starbursts compared to monofocal controls on a directed, validated, open-source questionnaire (QoV) in our prospective, multi-centre, Canadian clinical trial. With smoothed-edge, submicron diffractive echelettes and a distance-dominant design under mesopic conditions, the profile might appear to suggest a near vision tradeoff, but this was demonstrated not to be the case, as 84.3% of patients in the Canadian trial reported “no” or only “a little” difficulty seeing objects up close in poor or dim light.

Clareon PanOptix Pro. The most compelling data so far comes from a contralateral-eye study of 83 subjects comparing Pro to the original PanOptix. Visual acuity was non-inferior at distance, intermediate, and near, but the real differentiator was patient preference: nearly 2:1 in favour of the Pro eye, with most patients also preferring it for reduced halos and starbursts.

It’s an extraordinary moment in surgical vision correction technology. The options and side-effect profiles we have now are remarkable. My advice to colleagues: don’t be afraid to branch out beyond the platforms you’ve historically used.

Thanks to Liz Hunter and the Review of Ophthalmology team.

📖 May 2026 issue

Address

4935 40 Avenue NW #450
Calgary, AB
T3A2N1

Telephone

+14032863022

Website

Alerts

Be the first to know and let us send you an email when Dr. Adam Muzychuk posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Sponsored

Share

Category